The Twenty Minute VC (20VC): Venture Capital | Startup Funding | The Pitch

Snapshot · The Twenty Minute VC (20VC): Venture Capital | Startup Funding | The Pitch

20VC: $5BN in Revenue, 7 to 7,000 Employees in 9 Months, 206,000 Tests in a Single Day: The Craziest Story in Startups: Curative with Fred Turner

Explore episode Jul 18, 2026

Where this was said

When Did Fred Realise COVID Was Massive—and How Did Curative Scale to $5BN?

At 34:06 · chapter starts 21:00

The COVID chapter opens with Fred watching infection rate data on Twitter in mid-February 2020 and realising the trajectory was worse than anyone in public was admitting. With a COVID test already developed in his CSO's spare time but no lab license to run it, Fred scrambled — eventually striking a 50/50 JV with a sports doping lab in San Dimas, a small city best known as the setting of Bill & Ted's Excellent Adventure. Their first government customer was the San Dimas sheriff's department, followed quickly by the City of LA — a contract that came about because longevity investor Laura Deming tweeted about Curative's testing capacity and the Deputy Mayor slid into her DMs. To fund scaling, Curative collected daily invoices from LA with net-1 payment terms, sending someone to City Hall each morning to collect a check. The largest single contract — worth hundreds of millions — was Florida's statewide nursing home testing programme, which every other lab said was impossible to deliver. Fred explains the orthogonal supply chain philosophy: use no consumables your competitors are fighting over. Curative sourced swabs from electronics testing vendors, replaced magnetic bead extraction with filter plates that could be manufactured at scale, and built from scratch rather than optimising existing processes. Hiring was done with 5-minute interview slots in socially distanced parking lot queues. The peak came in December 2020: 206,000 tests in a single day, with 7,000 employees. The margin profile was brutal — highly profitable at surge peaks, deeply loss-making in the troughs between variants. Over three years, total revenue hit $5 billion. After paying out a 10x dividend to investors, roughly $500 million was reinvested into the health insurance company.

Similar snapshots